Modality
Vaccine
MOA
C5i
Target
SGLT2
Pathway
mTOR
AngelmanCrohn'sBladder Ca
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Sep 2031
ApprovedCurrent
NCT07479722
1,410 pts·Crohn's
2017-06→2031-09·Completed
NCT03460858
2,424 pts·Bladder Ca
2025-10→2028-03·Recruiting
NCT03562920
864 pts·Bladder Ca
2017-11→2030-08·Completed
4,698 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2028-03-142.0y awayPh3 Readout· Bladder Ca
2030-08-054.3y awayPh3 Readout· Bladder Ca
2031-09-145.5y awayPh3 Readout· Crohn's
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Complet…
Approved
Complet…
Approved
Recruit…
Catalysts
Ph3 Readout
2028-03-14 · 2.0y away
Bladder Ca
Ph3 Readout
2030-08-05 · 4.3y away
Bladder Ca
Ph3 Readout
2031-09-14 · 5.5y away
Crohn's
RecruitingCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07479722 | Approved | Crohn's | Completed | 1410 | CfB |
| NCT03460858 | Approved | Bladder Ca | Recruiting | 2424 | CfB |
| NCT03562920 | Approved | Bladder Ca | Completed | 864 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D |